Nature

Structural determinants of CCR5 recognition and HIV-1 blockade in RANTES

Certain chemokines act as natural antagonists of human immunodeficiency virus (HIV) by blocking key viral coreceptors, such as CCR5 and CXCR4, on the surface of susceptible cells. Elucidating the ...
Nasdaq

Manuscript Describes How CytoDyn’s Leronlimab Disrupts CCL5/RANTES-CCR5 Pathway, Thereby Restoring Immune Homeostasis, Reducing Plasma Viral Load, Reversing Hyper Immune ...

VANCOUVER, Washington, May 05, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist ...
Business Wire

IncellDx Files Patent for CCL5/RANTES Utility as a Diagnostic, Prognostic, and Therapeutic Biomarker in COVID-19 and Other Cytokine Storm Conditions

SAN FRANCISCO--(BUSINESS WIRE)--IncellDx announces the patent filing with the USPTO and the Pre-EUA with the FDA for CCL5/RANTES Utility as a Diagnostic, Prognostic, and Therapeutic Biomarker in COVID ...
Medscape

Chemokine May Be Prognostic for CVD in High-Risk Population

February 7, 2007 (Dallas, TX) - Plasma levels of RANTES, a chemokine with broad influence in the pathophysiology of atherosclerosis and acute coronary syndromes, were independently associated with a ...
ascopubs.org

Genetic polymorphisms of CCL5 and CCR5 to predict efficacy of cetuximab-based treatment in metastatic colorectal cancer patients depending on primary tumor location.

This is an ASCO Meeting Abstract from the 2017 ASCO Annual Meeting I. This abstract does not include a full text component.
ascopubs.org

Gene polymorphisms of CCL3, CCL4, CCL5, and CCR5 network in metastatic colorectal cancer patients treated with regorafenib.

Systemic impact on tumor growth after combined immuno-thermal ablation in a murine model of colorectal cancer. This is an ASCO Meeting Abstract from the 2020 Gastrointestinal Cancers Symposium. This ...
Nature

HIV-1 entry inhibitors: Evading the issue

The recent report in Nature Medicine that simultaneous inhibition of HIV-1 reverse transcriptase and protease does not prevent resistance to HIV-1 and will not be sufficient for its eradication 1 ...